PCL-R15 (PCL3000-b-R15 amphiphilic block polymer)
Sequence: Not a single peptide sequence; block copolymer PCL3000-b-R15 (poly(ε-caprolactone) ~3 kDa conjugated to polyarginine R15).
| Experiment Id | EXP001738 |
|---|---|
| Paper | Polyarginine-Mediated siRNA Delivery: A Mechanistic Study of Intracellular Trafficking of PCL-R15/si |
| Peptide | PCL-R15 (PCL3000-b-R15 amphiphilic block polymer) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | no |
| Peptide Concentration | |
| Rna Concentration | 100 nM siRNA (most in vitro assays; 4 h transfection). |
| Mixing Ratio | N/P = 40 (used for most cellular studies). |
| Formulation Format | PCL-R15 micelles + siRNA nanoplexes (electrostatic adsorption on micelle surface) |
| Formulation Components | PCL-R15 nanoparticles made by thin-film hydration (methanol film → hydrate with 5% glucose; 70 °C sonication). Nanoplexes formed by mixing equal volumes of PCL-R15 NP solution and siRNA in 5% glucose; vortex; stand 10 min. |
| Size Nm | 15.00 |
| Zeta Mv | 15.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa (human cervical cancer) |
| Animal Model | |
| Administration Route | |
| Output Type | in vitro gene silencing (protein) |
| Output Value | VEGF secretion downregulated vs untreated starting 24 h post-transfection; maximal suppression at ~72 h; effect persists up to 96 h. Sequence-specific (siNC shows no downregulation). |
| Output Units | |
| Output Notes | HeLa cells exposed to Opti-MEM containing PCL-R15/siVEGF (N/P 40; 100 nM) for 4 h, then changed to complete medium; VEGF measured by ELISA at time points. |
| Toxicity Notes | SRB assay: at 100 nM siRNA, PCL-R15/siRNA showed acceptable viability similar to R15/siRNA; higher siRNA concentrations increased PCL-R15 cytotoxicity. |
| Curation Notes |